Oral candidiasis and angular cheilitis

Dermatologic Therapy

Volumn 23, Issue 3, 2010, Pages 230-242

  Sharon, Victoria ^a   Fazel, Nasim ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angular cheilitis; Angular cheilosis; Candidosis; Oral candidiasis; Thrush

Indexed keywords

AMPHOTERICIN B; ANTACID AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; COTRIMOXAZOLE; CRYSTAL VIOLET; CYCLOSPORIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; POSACONAZOLE; PROTON PUMP INHIBITOR; PSEUDOMONIC ACID; GRAM'S STAIN; PHENAZINE DERIVATIVE;

ACUTE ATROPHIC CANDIDIASIS; ACUTE PSEUDOMEMBRANOUS CANDIDIASIS; AGING; ANGULAR CHEILITIS; ANOREXIA; BURNING MOUTH SYNDROME; BURNING SENSATION; CANDIDA ALBICANS; CHEILITIS; CHEILO CANDIDIASIS; CHRONIC ATROPHIC CANDIDIASIS; CHRONIC HYPERPLASTIC CANDIDIASIS; CHRONIC MULTIFOCAL CANDIDIASIS; DENTURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DYSGEUSIA; DYSPHAGIA; ENDOCRINE DISEASE; GASTROINTESTINAL SYMPTOM; GINGIVA DISEASE; GLOSSITIS; HEPATITIS; HUMAN; HYPOKALEMIA; HYPOSALIVATION; IMMUNOSUPPRESSIVE TREATMENT; INFANCY; INFECTION PREVENTION; LINEAR GINGIVAL ERYTHEMA; LIVER TOXICITY; LOADING DRUG DOSE; MEDIAN RHOMBOID GLOSSITIS; MOUTH HYGIENE; MOUTH MUCOSA ULCER; MOUTH ULCER; MUCOCUTANEOUS CANDIDIASIS; NAUSEA AND VOMITING; NEUTROPENIA; NUTRITIONAL DEFICIENCY; PATHOGENESIS; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN IRRITATION; SKIN MACERATION; SMOKING; TASTE AVERSION; THRUSH; WEIGHT REDUCTION; CANDIDIASIS, ORAL; CLASSIFICATION; MICROBIOLOGY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; CANDIDIASIS, ORAL; CHEILITIS; GENTIAN VIOLET; HUMANS; PHENAZINES; RISK FACTORS;

EID: 77952693197     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2010.01320.x     Document Type: Review

References (73)

1. Samaranayake LP, Keung Leung W, Jin L. Oral mucosal fungal infections. Periodontol 2000 2009 : 49 : 39 59.
2. Vazquez JA, Sobel JD. Mucosal candidiasis. Infect Dis Clin North Am 2002 : 16 : 793 820, v.
3. Arendorf TM, Walker DM. The prevalence and intra-oral distribution of Candida albicans in man. Arch Oral Biol 1980 : 25 : 1 10.
4. Wilkieson C, Samaranayake LP, MacFarlane TW, Lamey PJ, MacKenzie D. Oral candidosis in the elderly in long term hospital care. J Oral Pathol Med 1991 : 20 : 13 16.
5. Akpan A, Morgan R. Oral candidiasis. Postgrad Med J 2002 : 78 : 455 459.
6. Abu-Elteen KH, Abu-Alteen RM. The prevalence of Candida albicans populations in the mouths of complete denture wearers. New Microbiol 1998 : 21 : 41 48.
7. Scully C, el-Kabir M, Samaranayake LP. Candida and oral candidosis: a review. Crit Rev Oral Biol Med 1994 : 5 : 125 157.
8. Barlow AJ, Chattaway FW. Observations on the carriage of Candida albicans in man. Br J Dermatol 1969 : 81 : 103 106.
9. Arendorf TM, Walker DM. Oral candidal populations in health and disease. Br Dent J 1979 : 147 : 267 272.
10. Davenport JC. The oral distribution of Candida in denture stomatitis. Br Dent J 1970 : 129 : 151 156.
11. Pankhurst CL. Candidiasis (oropharyngeal). Clin Evid (Online) 2009 : March 18.
12. Pereira-Cenci T, Del Bel Cury AA, Crielaard W, Ten Cate JM. Development of Candida-associated denture stomatitis: new insights. J Appl Oral Sci 2008 : 16 : 86 94.
13. Vazquez JA, Sobel JD. Candidiasis. In : Dismukes WE, Pappas PG, Sobel JD, eds. Clinical mycology.
14. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995 : 20 : 115 125.
15. Greenspan D. Treatment of oropharyngeal candidiasis in HIV-positive patients. J Am Acad Dermatol 1994 : 31 : S51 55.
16. Barchiesi F, Morbiducci V, Ancarani F, Scalise G. Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. Eur J Epidemiol 1993 : 9 : 455 456.
17. Habif TP. Superficial Fungal Infections. In : Habif TP, ed. Clinical dermatology, 4th ed.
18. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998 : 26 : 259 274.
19. Liu X, Liu H, Guo Z, Luan W. Association of asymptomatic oral candidal carriage, oral candidiasis and CD4 lymphocyte count in HIV-positive patients in China. Oral Dis 2006 : 12 : 41 44.
20. Samaranayake LP. Oral mycoses in HIV infection. Oral Surg Oral Med Oral Pathol 1992 : 73 : 171 180.
21. Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 1998 : 27 : 1291 1294.
22. Ozog DM, Gogstetter DS, Scott G, Gaspari AA. Minocycline-induced hyperpigmentation in patients with pemphigus and pemphigoid. Arch Dermatol 2000 : 136 : 1133 1138.
23. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 1996 : 134 : 693 695.
24. Oliver DE, Shillitoe EJ. Effects of smoking on the prevalence and intraoral distribution of Candida albicans. J Oral Pathol 1984 : 13 : 265 270.
25. Soysa NS, Ellepola AN. The impact of cigarette/tobacco smoking on oral candidosis: an overview. Oral Dis 2005 : 11 : 268 273.
26. Cannon RD, Holmes AR, Mason AB, Monk BC. Oral Candida: clearance, colonization, or candidiasis? J Dent Res 1995 : 74 : 1152 1161.
27. Janik MP, Heffernan MP. Yeast Infections: Candidiasis and Tinea (Pityriasis) Versicolor. In : Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, eds. Fitzpatrick's dermatology in general medicine.
28. Samaranayake LP, Holmstrup P. Oral candidiasis and human immunodeficiency virus infection. J Oral Pathol Med 1989 : 18 : 554 564.
29. Golecka M, Oldakowska-Jedynak U, Mierzwinska-Nastalska E, Adamczyk-Sosinska E. Candida-associated denture stomatitis in patients after immunosuppression therapy. Transplant Proc 2006 : 38 : 155 156.
30. Ellepola AN, Samaranayake LP. Oral candidal infections and antimycotics. Crit Rev Oral Biol Med 2000 : 11 : 172 198.
31. Appleton SS. Candidiasis: pathogenesis, clinical characteristics, and treatment. J Calif Dent Assoc 2000 : 28 : 942 948.
32. Kahana M, Yahalom R, Schewach-Millet M. Recurrent angular cheilitis caused by dental flossing. J Am Acad Dermatol 1986 : 15 : 113 114.
33. MacFarlane TW, Helnarska SJ. The microbiology of angular cheilitis. Br Dent J 1976 : 140 : 403 406.
34. Reichart PA, Weigel D, Schmidt-Westhausen A, Pohle HD. Exfoliative cheilitis (EC) in AIDS: association with Candida infection. J Oral Pathol Med 1997 : 26 : 290 293.
35. Pons V, Greenspan D, Debruin M. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The multicenter study group. J Acquir Immune Defic Syndr 1993 : 6 : 1311 1316.
36. de Wet PM, Rode H, van Dyk A, Millar AJ. Perianal candidosis - a comparative study with mupirocin and nystatin. Int J Dermatol 1999 : 38 : 618 622.
37. Chernosky ME. Collagen implant in management of perleche (angular cheilosis). J Am Acad Dermatol 1985 : 12 : 493 496.
38. Odden K, Schenck K, Koppang H, Hurlen B. Candidal infection of the gingiva in HIV-infected persons. J Oral Pathol Med 1994 : 23 : 178 183.
39. Velegraki A, Nicolatou O, Theodoridou M, Mostrou G, Legakis NJ. Paediatric AIDS-related linear gingival erythema: a form of erythematous candidiasis? J Oral Pathol Med 1999 : 28 : 178 182.
40. Barr CE. Periodontal problems related to HIV-1 infection. Adv Dent Res 1995 : 9 : 147 151.
41. Reznik DA. Oral manifestations of HIV disease. Top HIV Med 2005 : 13 : 143 148.
42. Shikama N, Nusspaumer G, Hollander GA. Clearing the AIRE: on the pathophysiological basis of the autoimmune polyendocrinopathy syndrome type-1. Endocrinol Metab Clin North Am 2009 : 38 : 273 288, vii.
43. Hinshaw M, Longley BJ. Fungal Diseases. In : Lever WF, Elder DE, eds. Lever's histopathology of the skin.
44. Odman PA. The effectiveness of an enzyme-containing denture cleanser. Quintessence Int 1992 : 23 : 187 190.
45. Lal K, Santarpia RP 3rd., Pollock JJ, Renner RP. Assessment of antimicrobial treatment of denture stomatitis using an in vivo replica model system: therapeutic efficacy of an oral rinse. J Prosthet Dent 1992 : 67 : 72 77.
46. Douglas LJ. Surface composition and adhesion of Candida albicans. Biochem Soc Trans 1985 : 13 : 982 984.
47. Aframian DJ, Helcer M, Livni D, Robinson SD, Markitziu A, Nadler C. Pilocarpine treatment in a mixed cohort of xerostomic patients. Oral Dis 2007 : 13 : 88 92.
48. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009 : 48 : 503 535.
49. Nyst MJ, Perriens JH, Kimputu L, Lumbila M, Nelson AM, Piot P. Gentian violet, ketoconazole and nystatin in oropharyngeal and esophageal candidiasis in Zairian AIDS patients. Ann Soc Belg Med Trop 1992 : 72 : 45 52.
50. Balabanova M, Popova L, Tchipeva R. Dyes in dermatology. Clin Dermatol 2003 : 21 : 2 6.
51. Epstein JB. Antifungal therapy in oropharyngeal mycotic infections. Oral Surg Oral Med Oral Pathol 1990 : 69 : 32 41.
52. Barkvoll P, Hurlen B. Conventional treatment of oral candidiasis - new aspects. Nor Tannlaegeforen Tid 1989 : 99 : 116 119.
53. Cuttner J, Troy KM, Funaro L, Brenden R, Bottone EJ. Clotrimazole treatment for prevention of oral candidiasis in patients with acute leukemia undergoing chemotherapy. Results of a double-blind study. Am J Med 1986 : 81 : 771 774.
54. Konsberg R, Axell T. Treatment of Candida-infected denture stomatitis with a miconazole lacquer. Oral Surg Oral Med Oral Pathol 1994 : 78 : 306 311.
55. Dias AP, Samaranayake LP, Lee MT. Miconazole lacquer in the treatment of denture stomatitis: clinical and microbiological findings in Chinese patients. Clin Oral Investig 1997 : 1 : 47 52.
56. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994 : 330 : 263 272.
57. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J Am Acad Dermatol 1994 : 30 : 677 698 quiz 698-700.
58. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993 : 29 : S50 54.
59. Brammer KW, Coakley AJ, Jezequel SG, Tarbit MH. The disposition and metabolism of [14C]fluconazole in humans. Drug Metab Dispos 1991 : 19 : 764 767.
60. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994 : 30 : 911 933 quiz 916-934.
61. Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 1997 : 72 : 253 256.
62. Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997 : 24 : 28 34.
63. Maninder J, Usha A. Isolation, characterization and antifungal susceptibility pattern of Candida species causing oropharyngeal candidiasis in HIV positive patients. J Commun Dis 2008 : 40 : 177 181.
64. Leen CL, Dunbar EM, Ellis ME, Mandal BK. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. J Infect 1990 : 21 : 55 60.
65. Corvo R, Amichetti M, Ascarelli A, et al. Effects of fluconazole in the prophylaxis of oropharyngeal candidiasis in patients undergoing radiotherapy for head and neck tumour: results from a double-blind placebo-controlled trial. Eur J Cancer Care (Engl) 2008 : 17 : 270 277.
66. Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis 2005 : 41 : 1473 1480.
67. Saag MS, Fessel WJ, Kaufman CA, et al. Treatment of fluconazole- refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Res Hum Retroviruses 1999 : 15 : 1413 1417.
68. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993 : 37 : 778 784.
69. Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol 1997 : 37 : 535 540.
70. Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007 : 44 : 607 614.
71. Vazquez JA. Role of posaconazole in the management of oropharyngeal and esophageal candidiasis. Ther Clin Risk Manag 2007 : 3 : 533 542.
72. Ferretti GA, Ash RC, Brown AT, Largent BM, Kaplan A, Lillich TT. Chlorhexidine for prophylaxis against oral infections and associated complications in patients receiving bone marrow transplants. J Am Dent Assoc 1987 : 114 : 461 467.
73. Just-Nubling G, Gentschew G, Meissner K, et al. Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur J Clin Microbiol Infect Dis 1991 : 10 : 917 921.